newsfilter
← Latest News
PR Newswire·

RegeneRx Partner Signs LOI with Global Ophthalmology CRO for Two Phase 3 Clinical Trials in Neurotrophic Keratitis

ROCKVILLE, Md., July 18, 2022 /PRNewswire/ -- RegeneRx Biopharmaceuticals, Inc. (OTCQB:RGRX) ("RegeneRx" or "Company"), a clinical-stage drug development company focused on tissue protection, repair, and regeneration, is reporting today that its U.S. jo